Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the initial-line treatment of CML-CP. Five hundred and nineteen patients with newly diagnosed CML-CP have been randomly assigned to obtain dasatinib at a dose of one hundred mg the moment daily (259 clients) or https://chk1-in-413579.aboutyoublog.com/29616033/details-fiction-and-pha-665752